10x Genomics (NYSE:TXG) Director John R. Stuelpnagel sold 7,500 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $87.58, for a total value of $656,850.00. Following the transaction, the director now owns 574,987 shares in the company, valued at approximately $50,357,361.46. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
NYSE:TXG opened at $89.99 on Monday. 10x Genomics has a 52-week low of $45.11 and a 52-week high of $108.36. The business’s fifty day moving average is $82.35 and its 200 day moving average is $77.55.
10x Genomics (NYSE:TXG) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.09). The firm had revenue of $71.91 million during the quarter, compared to analysts’ expectations of $71.67 million. The company’s revenue was up 34.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.25) EPS.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Citigroup Inc. bought a new stake in shares of 10x Genomics in the 4th quarter worth $38,000. Baillie Gifford & Co. purchased a new position in shares of 10x Genomics in the 1st quarter worth $99,000. Russell Investments Group Ltd. purchased a new position in shares of 10x Genomics in the 1st quarter worth $119,000. Rockefeller Capital Management L.P. purchased a new position in 10x Genomics during the first quarter valued at $138,000. Finally, Bank of America Corp DE lifted its position in 10x Genomics by 2,716.0% during the fourth quarter. Bank of America Corp DE now owns 2,112 shares of the company’s stock valued at $161,000 after purchasing an additional 2,037 shares in the last quarter.
TXG has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. raised their price target on 10x Genomics from $90.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. Citigroup lifted their price target on 10x Genomics from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Cowen lifted their price target on 10x Genomics from $68.00 to $85.00 and gave the company an “outperform” rating in a research note on Tuesday, May 12th. Finally, Zacks Investment Research lowered 10x Genomics from a “buy” rating to a “hold” rating in a research note on Friday, May 22nd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $84.00.
10x Genomics Company Profile
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems. It offers chromium instruments, enzymes, reagents, microfluidic chips, and other consumable products, as well as software for analyzing biological systems.
Featured Article: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.